Finally, another piece of the puzzle emerges for suicide risk assessments

As the medical field has received technical innovation after technical innovation, psychiatry has been left with surprisingly litte. Now, with the EDOR-test, a new and objective method for assessing suicide risk in patients with a primary depression is available.

Take me to the product

What is hyporeactivity and the EDOR® test?

The EDOR test is based on analysing immediate and non- conscious electrodermal reactions to sound stimuli. Reaction patterns showing fast habituation are identified as hyporeactive, functioning as a marker for high risk of suicide and violent suicide attempts in patients with a primary depression.

Hyporeactivity as a suicide risk marker is stable over time, remains in remission and in later depression episodes. It is also independent from age, gender, symptoms of depression, severity or depth of depressive state and serotonin activity (5-HIAA in liquor).

How it can be used in clinical routine

Information provided by the test functions as an objective complement to the overall clinical interview and patient history. Combining information about patients with the EDOR Test provides a more complete basis for assessing suicide risk, a risk unknown to both patient and clinician.

EDOR Test information support assessing risk, and helps with: 


  • Managing limited psychiatric care resources by allocating costly activities or care time to the right patients
  • Decisions on treatment plans tailored to the patients’ needs and situation over time
  • Patient and treatment team communication

What the test can mean for the patient

Irrespective of test result, experience from clinical use is that the information can help the patient and ensuring a feeling that patients are taken seriously at the clinic.

Patients tested as hyporeactive many times value the increased contact with the caregiver and can provide a relief from feelings of guilt. Also, it serves as an explanation to why some measures are needed. Patients with a normal reactivity can lower some of their and their relatives’ anxiety, focusing on healing from their depressive episode.

More about the EDOR Method

Latest news

Emotra: Agreement with Italian research group

November 28th, 2018|Comments Off on Emotra: Agreement with Italian research group

Emotra AB (“Emotra”) is pleased to announce that we have reached an agreement with an Italian research group concerning so-called [...]

Emotra: Psychiatric hospital in London gets started

November 23rd, 2018|Comments Off on Emotra: Psychiatric hospital in London gets started

As Emotra announced in a press release on November 16, a letter of intent has been signed with a London-based [...]

Emotra: Important research study explains the biological mechanism behind EDOR® and hyporeactivity

November 20th, 2018|Comments Off on Emotra: Important research study explains the biological mechanism behind EDOR® and hyporeactivity

Emotra is proud to announce that Lars-Håkan Thorell, Emotra’s Head of Research and the inventor of EDOR®, in his research [...]

Emotra signs a letter of intent with a psychiatric hospital in England

November 16th, 2018|Comments Off on Emotra signs a letter of intent with a psychiatric hospital in England

Emotra hereby announces that the company has signed a letter of intent with a large, London-based psychiatric hospital. This deal [...]